<DOC>
	<DOC>NCT00735501</DOC>
	<brief_summary>This observational study is conducted in Europe. The study aims to observe the incidence of serious adverse drug reactions in subjects with type 2 diabetes during Levemir® treatment.</brief_summary>
	<brief_title>Observational Study to Observe the Safety of Levemir® Treatment in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<criteria>Any patient with type 2 diabetes Currently treated with basal human insulin therapy (basal only or in combination with oral glucose lowering drugs or other insulin) Selection of patients will be at the discretion of the treating physician after the decision to prescribe one of the study products to the patient Known or suspected allergy to study product(s) or related products. Pregnancy or breastfeeding or intention of becoming pregnant within the next 6 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>